Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2024-06-14 Capital/Financing Update
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2024, reporting a material definitive agreement entered into on June 10, 2024. It details a securities purchase agreement involving a private placement of common stock and warrants, a strategic alliance agreement, and a management services agreement. The document also includes information about unregistered sales of equity securities and references a press release. The content focuses on financing activities and agreements related to capital raising and strategic partnerships, not on financial results, management changes, or legal proceedings. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length and detail support a high confidence level.
2024-06-14 English
Delisting Announcement 2024
Delisting Announcement Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Vivos Therapeutics, Inc. It discusses the company's compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity and the initiation of delisting proceedings by Nasdaq. The document includes details about notices received, appeal rights, and the potential consequences of delisting. There are no financial statements or detailed financial data presented; rather, it is an official announcement regarding the delisting status and related regulatory communications. The document length is 7036 characters, which is sufficient for a detailed announcement but does not constitute a full financial report. Therefore, this filing is best classified as a Delisting Announcement (DLST).
2024-05-17 English
Earnings Release 2024
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 15, 2024, reporting the financial results for the first quarter ended March 31, 2024. It references a press release announcing these results, which is furnished as an exhibit. The text explicitly states that the press release is incorporated by reference and is not deemed filed for certain regulatory purposes. The document is short (4261 characters) and primarily serves as a current report to announce the earnings release rather than containing the full financial statements or detailed analysis itself. According to the classification rules, an initial announcement of quarterly financial results in a press release format within a Form 8-K is classified as an Earnings Release (ER).
2024-05-15 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Q1 2024
2024-05-14 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Vivos Therapeutics, Inc. It discusses the company's compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity and the risk of delisting if compliance is not maintained. The filing date is May 3, 2024, and it includes forward-looking statements and a signature from the CFO. The content focuses on a regulatory compliance update related to listing status and capital raising activities, not on financial results, management changes, or other report types. Form 8-K filings are current reports used to announce major events and updates, which fits the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2024-05-04 English
Regulatory Filings 2024
Regulatory Filings
2024-04-29 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.